View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 27, 2021

WCG acquires VeraSci to boost clinical trial offerings for CNS disorders

VeraSci will extend WCG’s capabilities to address the challenges related to the planning and implementation of CNS trials.

WCG has acquired VeraSci, which offers capabilities and eClinical software to design and perform clinical trials for central nervous system (CNS) disorders, to boost its trial technology and services.

Financial details were not disclosed.

VeraSci will support WCG’s scientific and patient engagement expertise, as well as CNS offerings, including those provided through its MedAvante, ProPhase and Analgesic Solutions units.

WCG expects the deal to help meet the rising demand for scientific and technological solutions that can enable the remote collection of data, hybrid virtual trials and entirely decentralised trials in main CNS therapy indications.

In addition, VeraSci will enhance WCG’s capabilities to address the challenges related to CNS trial planning and implementation.

VeraSci has experience across all development phases, from single-centre, Phase I trials to international Phase III trials.

WCG executive chairman and CEO Donald Deieso said: “On behalf of WCG, I’m proud to welcome VeraSci, an organisation that shares our dedication to improving the clinical trial experience for patients and sites, commitment to scientific rigour and passion for bringing novel technologies into clinical trial processes.”

VeraSci portfolio consists of solutions to enhance data quality in trials, which include endpoint and assessment services, rater training and certification, language and translation support, along with eCOA and ePRO technologies.

The company’s Pathway technology platform is designed for easy adoption to any study worldwide.

VeraSci uses Pathway to capture data that enables the evaluation of symptoms, cognition and functional capacity in a variety of therapeutic areas.

VeraSci CEO and co-founder Rich Keefe said: “Since our inception, we have invested in expanding VeraSci’s expertise and capabilities to include a variety of clinical and regulatory endpoints covering a range of diseases and disorders.

“We have also pioneered technological advances that are changing the way subjective endpoint assessments are conducted in clinical research.”

The company will leverage the acquisition to scale up and bolster its offerings.

VeraSci will operate as WCG VeraSci and continue its leadership structure. It will also retain its headquarters in North Carolina, US.

In May, WCG acquired The Avoca Group to expand its portfolio of solutions for enhancing clinical trial quality management and compliance transformation.


Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena